

# **TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Pipeline Review, H2 2017**

<https://marketpublishers.com/r/T7567694609EN.html>

Date: November 2017

Pages: 31

Price: US\$ 3,500.00 (Single User License)

ID: T7567694609EN

## **Abstracts**

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Pipeline Review, H2 2017

### **SUMMARY**

According to the recently published report 'TGF Beta Receptor Type 2 - Pipeline Review, H2 2017'; TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies.

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Transforming growth factor beta receptor II is a TGF beta receptor encoded by TGFBR2 gene. It regulates physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of TGFBR1 and 2 TGFBR2 molecules results in the phosphorylation and the activation of TGFRB1 by the constitutively active TGFBR2.

The report 'TGF Beta Receptor Type 2 - Pipeline Review, H2 2017' outlays comprehensive information on the TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical and Discovery stages are 3 and 3 respectively. Report covers products from therapy areas Oncology, Cardiovascular, Dermatology and Respiratory which include indications Breast Cancer, Congestive Heart Failure (Heart Failure), Epithelial Tumor, Glioblastoma Multiforme (GBM), Multiple Myeloma (Kahler Disease), Pancreatic Cancer, Pulmonary Fibrosis, Scar and Wounds.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30)

The report reviews TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted therapeutics and enlists all their major and minor projects

The report assesses TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFR2 or EC 2.7.11.30) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFR2 or EC 2.7.11.30)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFR2 or EC 2.7.11.30) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFB2 or EC 2.7.11.30) - Overview

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFB2 or EC 2.7.11.30) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFB2 or EC 2.7.11.30) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFB2 or EC 2.7.11.30) - Companies Involved in Therapeutics Development

Eli Lilly and Co

InteRNA Technologies BV

Oncodesign SA

Oncomatrix Biopharma SL

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFB2 or EC 2.7.11.30) - Drug Profiles

ITD-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

miRNA-520f - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Antagonize TGF Beta Receptor Type 2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMTX-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Transforming Growth Factor Beta Receptor II for Oncology -

Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Antagonize TGF-Beta Receptor Type 1 and 2 for Diabetic Foot  
Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or  
TGFB2 or EC 2.7.11.30) - Dormant Products

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or  
TGFB2 or EC 2.7.11.30) - Discontinued Products

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or  
TGFB2 or EC 2.7.11.30) - Product Development Milestones

Featured News & Press Releases

Nov 14, 2012: Small molecule makes heart cells out of stem cells

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indication, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Eli Lilly and Co, H2 2017

Pipeline by InterRNA Technologies BV, H2 2017

Pipeline by Oncodesign SA, H2 2017

Pipeline by Oncomatrix Biopharma SL, H2 2017

Dormant Projects, H2 2017

Discontinued Products, H2 2017

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

### COMPANIES MENTIONED

Eli Lilly and Co

InteRNA Technologies BV

Oncodesign SA

Oncomatryx Biopharma SL

## I would like to order

Product name: TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Pipeline Review, H2 2017

Product link: <https://marketpublishers.com/r/T7567694609EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T7567694609EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

